iBio, Inc.

🌟 iBio, Inc. is proud to attend the Antibody Engineering & Therapeutics Conference in our hometown of San Diego this week! 🌟 Our leaders, Kristi Sarno, SVP of Business Development, and Cory Schwartz, Director of Drug Discovery, are on the ground representing iBio’s cutting-edge advancements in AI-driven antibody discovery and development. This event is pivotal for showcasing how iBio's Machine Learning Antibody Discovery Engine and technologies like Epitope Steering, ShieldTx™, and EngageTx™ are accelerating the creation of first-in-class and best-in-class therapeutics. By addressing hard-to-drug targets and reducing preclinical timelines, we're shaping the future of cardio-metabolic therapeutics and immuno-oncology drugs. As San Diego continues to thrive as a biotech hub, our presence reflects iBio's commitment to innovation and collaboration within this vibrant #biotech ecosystem. Conferences like these are where strategic partnerships form, groundbreaking ideas emerge, and the future of antibody engineering takes shape. 💡 Let’s connect! If you’re at the conference, we’d love to discuss how #iBio can support your pipeline goals or explore partnership opportunities. #AntibodyEngineering #MachineLearning #ImmunoOncology #SanDiegoBiotech #Collaboration #iBio

👋 Welcome, Shalini Varma, to iBio, Inc. 👋 We are delighted to welcome Shalini Varma as iBio's new Lead of CMC and Nonclinical Development. With her extensive experience and a proven track record in advancing innovative therapies from the lab to the clinic, Shalini will play a pivotal role in driving our AI-driven drug discovery programs in cardiometabolic diseases and immuno-oncology. We look forward to her contributions as iBio continues to advance our mission of delivering next-generation drugs. #iBio #DrugDiscovery #MachineLearning #LabtoClinic

💡 Exciting Developments in Immuno-Oncology! 💡 Earlier this week, Janux Therapeutics announced positive Phase 1 data for JANX007, a masked T-cell engager targeting metastatic prostate cancer. These findings align with our preclinical observations and reinforce the potential of conditionally activated bispecifics like those developed with iBio’s ShieldTx™ technology. This allows us to target diseased tissue without harming healthy tissue. ShieldTx™ leverages machine learning and engineered epitopes to design conditionally active, masked antibodies. This technology ensures antibodies remain inactive until they reach diseased tissue, minimizing harm to healthy cells. Our approach goes further by repurposing epitopes as masks, mimicking natural targets, and improving safety and development timelines. At iBio, we’re advancing conditionally active therapies, including a Trop2 x CD3 bispecific and masked antibodies against MUC16, both for solid tumors. These breakthroughs validate the broader potential of conditionally activated bispecifics in oncology. Collaboration and innovation pave the way for safer, more effective cancer treatments. Let’s keep pushing the boundaries of what’s possible! Read more here: https://bit.ly/3BqMFMR #iBio #BioTech #ImmunoOncology #BiotechInnovation #MachineLearning #AntibodyEngineering

📢 iBio, Inc. Welcomes Two New Board Members 📢 We're thrilled to announce the addition of two outstanding leaders to our iBio Board of Directors. These appointments confirm iBio’s commitment to accelerating innovation in AI-driven precision antibody discovery and align with our vision of revolutionizing drug development in immuno-oncology and metabolic diseases. With expertise in biotechnology, strategy, finance, and transformative leadership, our new members bring invaluable insights that will guide iBio as we advance our preclinical pipeline and explore high-potential opportunities for asset out-licensing. Please help us welcome #biotech veterans David Arkowitz and António Parada! Together, we’re strengthening our leadership to drive forward our mission: designing first-in-class and best-in-class therapeutics through cutting-edge machine-learning platforms like Epitope Steering™ and ShieldTx™. The full release is linked below. #Leadership #Innovation #AntibodyDiscovery #Biotechnology #iBio

PEGS Europe 2024 Poster Presentation Last week, our Chief Executive Officer & Chief Science Officer, Dr. Martin Brenner, presented its antibody engineering platform at the PEGS Europe Conference in Lisbon. The poster showcased how machine learning (ML) and mammalian display technologies accelerate the development of next-generation CD3-based T-cell engagers for cancer immunotherapy. This work represents iBio’s commitment to advancing immuno-oncology through cutting-edge AI and biologics innovation. We're proud to be a leader in developing innovative, safer, and more effective drugs. Are you curious to learn more about our platform or discuss collaboration opportunities? Reach out or explore our latest updates. #AI #iBio #ImmunoOncology #DrugDiscovery #PEGS2024 #TCellEngagers

Exciting news! Tomorrow, Martin Brenner, DVM, Ph.D., CEO & CSO of iBio, Inc., will present groundbreaking work at PEGS Europe. 💡 His poster, "ML-Guided Epitope Steering and Antibody Optimization with Mammalian Display Generates a Diverse Panel of CD3 T-Cell Engagers," showcases iBio's proprietary approach to AI-driven antibody discovery. Martin's insights promise to shed light on how AI and machine learning can revolutionize biologics and drug discovery, delivering diverse, high-potential CD3 T-cell engages. Are you attending #PEGSEUROPE2024? Connect with Martin and attend his presentation tomorrow. #drugdiscovery #PegsEurope #Conference #Presentation #iBio #MachineLearning

🛫 iBio, Inc. is headed to Texas for The Obesity Society's #ObesityWeek 🛫 🔬 iBio’s Principal Scientist, Tom Hsu, will join leading experts at ObesityWeek® in San Antonio, TX! This premier event gathers global professionals focused on tackling obesity, one of our time's most pressing health challenges. At iBio, we're advancing antibody therapeutics in the metabolic disease space through our strategic partnerships and AI-powered discovery platform. Leveraging tools like Epitope Steering and ShieldTx™, our goal is to engineer innovative therapies that meet the unique needs of patients dealing with obesity and related metabolic conditions. Exciting developments lie ahead as we continue exploring collaborative opportunities to bring novel, AI-driven therapeutics to life. If you’re attending ObesityWeek®, don’t miss the chance to connect with Tom Hsu and discuss the future of precision therapeutics at iBio for metabolic diseases! #iBio #ObesityWeek #metabolicdisease #biotech #AI #drugdiscovery

📢 "Tomorrow's Precision Antibody Therapeutics Powered by Machine Learning" Unveiled at #BioFuture2024 📢 Yesterday, our CEO and CSO, Martin Brenner, captivated the audience with insights into iBio’s pioneering approach to antibody discovery, aptly titled "Tomorrow's Precision Antibody Therapeutics Powered by Machine Learning," and our journey from a CDMO to a Machine-Learning-Enabled Antibody Discovery company. Martin showcased how our cutting-edge AI-driven platforms—including Epitope Steering, ShieldTx™, and StableHu™—are advancing the development of best-in-class therapies. Our proprietary technologies are engineered to unlock challenging, high-impact targets in immuno-oncology and cardio-metabolic diseases, promising faster discovery times and enhanced precision. With these advancements, #iBio is shaping the future of precision medicine. Stay connected as we push the boundaries of what’s possible in #drugdiscovery! #BioFuture2024 #PrecisionMedicine #AntibodyTherapeutics #MachineLearning

🚨 iBio, Inc. Expands #BioEurope2024 Attendance in Sweden 🚨 iBio’s SVP of Business Development, Kristi Sarno, will attend BIO-Europe 2024 in Stockholm, Sweden, from November 4–6. She’ll join our CFO, Felipe D., to showcase iBio’s latest advancements in AI-driven drug discovery and explore potential collaborations. This is a great opportunity to learn more about iBio's drug discovery platform and innovations in immuno-oncology and metabolic diseases. If you’re attending, don’t miss the chance to connect with Kristi and Felipe! #BIOEurope #BusinessDevelopment #AIInBiotech #DrugDiscovery #Biologics #ImmunoOncology

🌍 Exciting News! iBio, Inc.'s Chief Financial Officer, Felipe D., will be attending #BioEurope2024 in Stockholm, Sweden, next month! 🌍 This key event brings together top biotech and pharma leaders and over 5,000 industry professionals. Felipe will discuss iBio’s innovative AI-driven platform and explore potential partnerships for our growing pipeline in immuno-oncology and cardiometabolic diseases. At iBio, we're leveraging machine learning and epitope engineering to accelerate drug discovery and development—making major strides in tackling some of the most challenging targets. 💡 Interested in connecting with Felipe? Drop a message or schedule a meeting at the event! Let’s explore how we can collaborate. #BioEurope #Biotech #AI #ImmunoOncology #Cardiometabolic #MachineLearning #Partnerships #DrugDiscovery #Pharma #iBio